%0 Journal Article
%T Investigation of TSPO variants in schizophrenia and antipsychotic treatment outcomes.
%A Pouget JG
%A Gonçalves VF
%A Nurmi EL
%A P Laughlin C
%A Mallya KS
%A McCracken JT
%A Aman MG
%A McDougle CJ
%A Scahill L
%A Misener VL
%A Tiwari AK
%A Zai CC
%A Brandl EJ
%A Felsky D
%A Leung AQ
%A Lieberman JA
%A Meltzer HY
%A Potkin SG
%A Niedling C
%A Steimer W
%A Leucht S
%A Knight J
%A Müller DJ
%A Kennedy JL
%J Pharmacogenomics
%V 16
%N 1
%D Jan 2015
%M 25560467
%F 2.638
%R 10.2217/pgs.14.158
%X <B>OBJECTIVE: </B>TSPO is a neuroinflammatory biomarker and emerging therapeutic target in psychiatric disorders. We evaluated whether TSPO polymorphisms contribute to interindividual variability in schizophrenia, antipsychotic efficacy and antipsychotic-induced weight gain.<BR><B>METHODS: </B>We analyzed TSPO polymorphisms in 670 schizophrenia cases and 775 healthy controls. Gene-gene interactions between TSPO and other mitochondrial membrane protein-encoding genes (VDAC1 and ANT1) were explored. Positive findings were evaluated in two independent samples (Munich, n = 300; RUPP, n = 119).<BR><B>RESULTS: </B>TSPO rs6971 was independently associated with antipsychotic-induced weight gain in the discovery (puncor = 0.04) and RUPP samples (p = 3.00 × 10(-3)), and interacted with ANT1 rs10024068 in the discovery (p = 1.15 × 10(-3)) and RUPP samples (p = 2.76 × 10(-4)).<BR><B>CONCLUSIONS: </B>Our findings highlight TSPO as a candidate for future investigations of antipsychotic-induced weight gain, and support the involvement of mitochondrial membrane components in this serious treatment side effect.